# Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation

> **NCT05042505** · NA · COMPLETED · sponsor: **Medanta, The Medicity, India** · enrollment: 100 (actual)

## Conditions studied

- Diabetes Mellitus
- Liver Transplant; Complications

## Interventions

- **DRUG:** Dapagliflozin 10Mg Tab
- **DRUG:** Sitagliptin 100mg

## Key facts

- **NCT ID:** NCT05042505
- **Lead sponsor:** Medanta, The Medicity, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-05
- **Final completion:** 2026-02-27
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042505, "Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05042505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*